E-mail  |   Log in
News Center
Ningbo Aucheer Biotechnology Co., Ltd
audir
audir
Maternal and Child Health | Study on the Changes of PLGF in the Plasma of Pregnant Women with Preeclampsia

Maternal and Child Health | Study on the Changes of PLGF in the Plasma of Pregnant Women with Preeclampsia

(Summary description)

Maternal and Child Health | Study on the Changes of PLGF in the Plasma of Pregnant Women with Preeclampsia

(Summary description)

                                              图片

 

Preeclampsia is a kind of hypertensive disorder during pregnancy. The common clinical manifestations are hypertension and proteinuria. Its condition is serious and changes rapidly. It is a systemic syndrome. In different women, it affects many organs including the central nervous system, kidney, liver and blood coagulation cascade to varying degrees.

According to the time of onset, it is divided into early-onset preeclampsia and late-onset preeclampsia. Studies have shown that early-onset preeclampsia is caused by placental defects, while late-onset preeclampsia may be caused by normal aging of the placenta and maternal cardiovascular and Caused by the interaction between genetic susceptibility to metabolic diseases. Placental growth factor (PLGF), a member of the vascular endothelial cell growth factor family, has a unique regulatory effect on the functions of trophoblast cells and endothelial cells, can promote angiogenesis, and has a certain correlation with the occurrence of PE.

 

图片

 

The Suzhou Jiulong Hospital affiliated to Shanghai Jiaotong University School of Medicine selected 92 cases of preeclampsia pregnant women as the experimental group, and 50 healthy pregnant women during the same period as the control group. The plasma PLGF of each group was studied and analyzed. The 92 pregnant women with PE were divided into mild PE group (M-PE group, n=53) and severe PE group (S-PE group, n=39) according to their severity, and divided into early-onset PE group (n=39) according to the time of onset =57) and late-onset PE group (n=35), the PLGF content in plasma was detected by enzyme-linked immunosorbent assay. The results showed that the plasma PLGF expression in patients with preeclampsia was significantly low, and it was related to the onset period and severity of the disease. The abnormal expression of early-onset preeclampsia is more prominent.

PLGF participates in the growth and migration of vascular endothelial cells. The secretion of PLGF in the early pregnancy is less, and it gradually increases with the prolongation of the gestational week, reaching a peak at 29-32 weeks of gestation, and then gradually decreasing thereafter. Although the clinical signs of preeclampsia appear in the middle and late pregnancy, pathological changes related to it have appeared in the early pregnancy. And the severity of preeclampsia is closely related to the onset of onset, the earlier the onset, the more severe the condition.

Therefore, it is particularly important to study biomarkers that can predict early preeclampsia and to screen early predictive indicators of preeclampsia. The 2019 International Federation of Obstetrics and Gynecology (FIGO) pointed out that the best biochemical index in early pregnancy screening is PLGF. The Guidelines for the Diagnosis and Treatment of Hypertension in Pregnancy (2020) also clearly stated that the best predictive method is to combine the risk factors of pregnant women with their MAP, PLGF, and Uterine Artery Pulsatility Index (UTPI) with higher accuracy.

Anyuxi™ Placental Growth Factor Detection Kit

 

Among all the forces that focus on pre-eclampsia diseases and patients, Aucheer is also one of them. It has been committed to providing professional maternal and child health clinical diagnosis solutions. Anyuxi™ Placental Growth Factor Detection Kit can be used for pre-eclampsia Carry out risk assessment and assist clinical diagnosis to identify preeclampsia. Screen at the right time, identify the enemy's situation, and prevent it early! Regular prenatal screening is conducive to the early detection of prenatal complications. According to the correct guidance of the condition and formulating scientific diagnosis and treatment plans, the significance of prenatal preventive screening can be realized and the purpose of ensuring the health of mothers and babies is achieved.

图片

相关资讯

Aucheer
Contact:86-574-87732259
Technical Support:400-008-6588
Aucheer
Business Mailbox:info1@aucheer.net
HR Mailbox :hr@aucheer.net
Aucheer
Address: North Building B, No. 885, Chunhua Rd., Wangchun Industrial Zone, Haishu District, Ningbo, Zhejiang Province, China 
Aucheer
Aucheer Bio
Aucheer
Aucheer Medical

© 2021 Ningbo Aucheer Biotechnology Co., Ltd | 浙ICP备17032133号-2Powered by www.300.cn